Abstract: The present application provides anti-CD137 constructs that bind to CD137 (e.g., anti-CD137 monoclonal antibodies and multispecific antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD137 constructs, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD137 constructs, pharmaceutical compositions containing the anti-CD137 constructs, and methods of using the anti-CD137 constructs or compositions.

Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3.

Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3. The antibody derivative is a multispecific antibody that binds to GPC3 and an additional antigen, e.g., 4-1BB.

Abstract: Provided are antibodies and antibody derivatives that bind to GARP (also known as LRRC32 and CPPRDD) and/or GARP/TGF? complexand methods of using the same. In certain embodiments, an anti-GARP/TGF? antibody or antibody derivative provided herein can inhibit a TGF? signal pathway in a target cell.

Abstract: The present disclosure relates to antibodies and antibody derivatives that bind to CD47 (also known as IAP, MER6 and OA3) and methods of using the same. In certain embodiments, an anti-CD47 antibody or antibody derivative disclosed herein exhibits reduced binding to a red blood cell.

Abstract: The present invention relates to anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT.

Abstract: Provided in the present invention are an anti-LAG3 monoclonal antibody and the use thereof. Further provided are a nucleotide molecule for encoding the antibody, an expression vector and a host cell for expressing the antibody, a composition containing the antibody, and the use of the antibody in the preparation of drugs for resisting tumors, treating autoimmune diseases, and treating infectious diseases and/or resisting transplantation rejection reactions.

Abstract: Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. The anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. The one or more additional antigen comprises Programmed death protein 1 (PD1).

Abstract: The present invention provides anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigen, and methods of using the same. In certain embodiments, the one or more additional antigen comprises epidermal growth factor receptor (EGFR).

Abstract: Provided are anti-TIGIT antibodies that bind to “T cell immunoreceptor with Ig and ITIM domains (TIGIT)”, including multispecific anti-TIGIT antibodies with binding specificity for TIGIT and one or more additional antigen, and methods of using the same. In certain embodiments, the anti-TIGIT antibodies comprises a single domain antibody that binds to TIGIT. In certain embodiments, the one or more additional antigen comprises Programmed cell death ligand 1 (PDL1).

Abstract: Provided are anti-CD137 constructs that bind to CD137, including multispecific anti-CD137 antibodies with binding specificity for CD137 and one or more additional antigens, and methods of using the same. In certain embodiments, the one or more additional antigens comprise human epidermal growth factor receptor 2 (HER2).

Abstract: Provided are anti-CD73 antibodies, variants, and antigen binding fragments thereof. The antibodies, the variants, and the antigen binding fragments thereof bind to human CD73 with high affinity, and suppress the enzymatic activity of CD73, and optionally induce CD73 internalization. Further provided are isolated nucleic acid molecules encoding the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof, and a related expression vector and a host cell. Provided is a method for preparing the anti-CD73 antibodies, the variants, and the antigen binding fragments thereof. Further provided are related pharmaceutical compositions and a method for using said pharmaceutical compositions in treating a subject.

Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.

Abstract: Provided are anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-VEGFR2 antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-VEGFR2 antibodies and antigen binding fragments thereof. Also provided are related pharmaceutical compositions comprising anti-VEGFR2 antibodies (or antigen binding fragments thereof) and methods of their use in the treatment of pathological conditions characterized by excessive angiogenesis.

Abstract: Provided are anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-EGFR antibodies or antigen binding fragments thereof, related expression vectors, and host cells. Provided are methods of making anti-epidermal growth factor receptor (EGFR) antibodies, aglycosylated CDR-H2 anti-EGFR antibodies, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects.

Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.

Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.